Erste Asset Management GmbH Buys Shares of 2,790 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Erste Asset Management GmbH bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,790 shares of the company's stock, valued at approximately $1,428,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Cobblestone Capital Advisors LLC NY lifted its stake in shares of IDEXX Laboratories by 1.0% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 24,484 shares of the company's stock worth $12,370,000 after buying an additional 244 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its holdings in IDEXX Laboratories by 151.3% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 85,927 shares of the company's stock valued at $43,412,000 after buying an additional 51,728 shares during the period. Verition Fund Management LLC increased its holdings in IDEXX Laboratories by 20.5% in the 3rd quarter. Verition Fund Management LLC now owns 6,508 shares of the company's stock valued at $3,288,000 after buying an additional 1,108 shares during the period. Icon Wealth Advisors LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $264,000. Finally, Rockefeller Capital Management L.P. grew its holdings in shares of IDEXX Laboratories by 0.9% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 52,744 shares of the company's stock valued at $26,650,000 after purchasing an additional 448 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX traded up $2.32 during mid-day trading on Wednesday, reaching $434.43. 1,303,295 shares of the company traded hands, compared to its average volume of 511,002. The stock has a market capitalization of $35.58 billion, a P/E ratio of 41.89, a P/E/G ratio of 3.76 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The company's fifty day moving average price is $447.62 and its 200-day moving average price is $475.46. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.53 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.18% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday. JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Barclays decreased their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Finally, Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research note on Thursday, October 10th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $546.56.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.